Overview

Pregabalin In Partial Seizures Extension Study

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Pregabalin